Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Grimm, Martin ^a   Gasser, Martin ^a   Bueter, Marco ^a   Strehl, Johanna ^a   Wang, Johann ^a   Nichiporuk, Ekaterina ^a   Meyer, Detlef ^b   Germer, Christoph T ^a   Waaga Gasser, Ana M ^a   Thalheimer, Andreas ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Leopoldina Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYTOKINE; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CD4 ANTIGEN; FASLG PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOMA CELL; CD4+ CD25+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LIVER METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; COLORECTAL TUMOR; DISEASE MODEL; IMMUNOLOGY; LIVER TUMOR; METASTASIS; PATHOLOGY;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD95; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PHENOTYPE;

EID: 77950429078     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-82     Document Type: Article

References (46)

1. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C. Prognostic Factors in Colorectal Cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 7:979-994.
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic Metastases From Colorectal Carcinoma: Impact of Surgical Resection on the Natural History. Br J Surg 1990, 11:1241-1246. 10.1002/bjs.1800771115.
3. Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, Encke A, Muller HH. Surgical Resection of Liver Metastases of Colorectal Carcinoma: Short and Long-Term Results. Semin Oncol 2000, 5(Suppl 10):112-119.
4. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of Antitumor Immunity by IL-10 and TGF-Beta-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells. J Immunol 2006, 2:896-904.
5. Elkord E, Hawkins RE, Stern PL. Immunotherapy for Gastrointestinal Cancer: Current Status and Strategies for Improving Efficacy. Expert Opin Biol Ther 2008, 4:385-395.
6. Khong HT, Restifo NP. Natural Selection of Tumor Variants in the Generation of "Tumor Escape" Phenotypes. Nat Immunol 2002, 11:999-1005.
7. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The Significance of Treg Cells in Defective Tumor Immunity. Arch Immunol Ther Exp (Warsz) 2008, 3:181-191.
8. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo O, Moser M. CD4+ CD25+ Regulatory T Cells Control T Helper Cell Type 1 Responses to Foreign Antigens Induced by Mature Dendritic Cells in Vivo. J Exp Med 2003, 2:259-266.
9. Cui G, Florholmen J. Polarization of Cytokine Profile From Th1 into Th2 Along Colorectal Adenoma-Carcinoma Sequence: Implications for the Biotherapeutic Target?. Inflamm Allergy Drug Targets 2008, 2:94-97.
10. Bueter M, Gasser M, Schramm N, Lebedeva T, Tocco G, Gerstlauer C, Grimm M, Nichiporuk E, Thalheimer A, Thiede A, Meyer D, Benichou G, Waaga-Gasser AM. T-Cell Response to P53 Tumor-Associated Antigen in Patients With Colorectal Carcinoma. Int J Oncol 2006, 2:431-438.
11. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ Regulatory Cells Uncovers Immune Responses to Shared Murine Tumor Rejection Antigens. Eur J Immunol 2002, 11:3267-3275.
12. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T Cells in Tumors From Patients With Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer. Cancer Res 2001, 12:4766-4772.
13. Sakaguchi S. Regulatory T Cells: Key Controllers of Immunologic Self-Tolerance. Cell 2000, 5:455-458.
14. Mills KH. Regulatory T Cells: Friend or Foe in Immunity to Infection?. Nat Rev Immunol 2004, 11:841-855.
15. Hisaeda H, Maekawa Y, Iwakawa D, Okada H, Himeno K, Kishihara K, Tsukumo S, Yasutomo K. Escape of Malaria Parasites From Host Immunity Requires CD4+ CD25+ Regulatory T Cells. Nat Med 2004, 1:29-30.
16. Yu P, Fu YX. Tumor-Infiltrating T Lymphocytes: Friends or Foes?. Lab Invest 2006, 3:231-245.
17. Jakowlew SB. Transforming Growth Factor-Beta in Cancer and Metastasis. Cancer Metastasis Rev 2006, 3:435-457.
18. Kollmar O, Schilling MK, Menger MD. Experimental Liver Metastasis: Standards for Local Cell Implantation to Study Isolated Tumor Growth in Mice. Clin Exp Metastasis 2004, 5:453-460.
19. Thalheimer A, Otto C, Bueter M, Illert B, Gattenlohner S, Gasser M, Meyer D, Fein M, Germer CT, Waaga-Gasser AM. The Intraportal Injection Model: a Practical Animal Model for Hepatic Metastases and Tumor Cell Dissemination in Human Colon Cancer. BMC Cancer 2009, 29. 10.1186/1471-2407-9-29, 2648996, 19166621.
20. Burnet M. Cancer: a Biological Approach. III. Viruses Associated With Neoplastic Conditions. IV. Practical Applications. Br Med J 1957, 5023:841-847.
21. Chan WS, Page CM, Maclellan JR, Turner GA. The Growth and Metastasis of Four Commonly Used Tumour Lines Implanted into Eight Different Sites: Evidence for Site and Tumour Effects. Clin Exp Metastasis 1988, 3:233-244.
22. Isbert C, Boerner A, Ritz JP, Schuppan D, Buhr HJ, Germer CT. In Situ Ablation of Experimental Liver Metastases Delays and Reduces Residual Intrahepatic Tumour Growth and Peritoneal Tumour Spread Compared With Hepatic Resection. Br J Surg 2002, 10:1252-1259.
23. Chambers AF, Groom AC, MacDonald IC. Dissemination and Growth of Cancer Cells in Metastatic Sites. Nat Rev Cancer 2002, 8:563-572.
24. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N Engl J Med 2003, 3:203-213.
25. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence That Specific T Lymphocytes May Participate in the Elimination of Chronic Myelogenous Leukemia. Nat Med 2000, 9:1018-1023.
26. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R. Clinical Significance of Serum Th1-, Th2- and Regulatory T Cells-Associated Cytokines in Adult T-Cell Leukemia/Lymphoma: High Interleukin-5 and -10 Levels Are Significant Unfavorable Prognostic Factors. Int J Cancer 2006, 12:3054-3061.
27. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A. CD3+ Cells at the Invasive Margin of Deeply Invading (PT3-T4) Colorectal Cancer and Risk of Post-Surgical Metastasis: a Longitudinal Study. Lancet Oncol 2009, 9:877-884.
28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival. Nat Med 2004, 9:942-949.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 2006, 5795:1960-1964.
30. Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD, Buttenshaw RL, Lincoln D, Clouston AD, Jass JR, Radford-Smith GL. Characterization of Tumour-Infiltrating Lymphocytes and Apoptosis in Colitis-Associated Neoplasia: Comparison With Sporadic Colorectal Cancer. J Pathol 2006, 3:381-387.
31. Clarke SL, Betts GJ, Plant A, Wright KL, El Shanawany TM, Harrop R, Torkington J, Rees BI, Williams GT, Gallimore AM, Godkin AJ. CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients With Colorectal Cancer. PLoS One 2006, e129. 10.1371/journal.pone.0000129, 1762416, 17205133.
32. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In Situ Analysis of FOXP3+ Regulatory T Cells in Human Colorectal Cancer. J Transl Med 2006, 52. 10.1186/1479-5876-4-52, 1764431, 17166272.
33. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz D, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells With IFN-Gamma-Dependent Antiangiogenic Activity, As Well As Long-Lasting Tumor Immunity Elicited by Peptide Vaccination. J Immunol 2003, 11:5931-5939.
34. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J Clin Oncol 2009, 2:186-192.
35. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J. Identification of CD8+CD25+Foxp3+ Suppressive T Cells in Colorectal Cancer Tissue. Gut 2009, 4:520-529.
36. Mosmann TR, Sad S. The Expanding Universe of T-Cell Subsets: Th1, Th2 and More. Immunol Today 1996, 3:138-146.
37. Romagnani S. The Th1/Th2 Paradigm. Immunol Today 1997, 6:263-266.
38. Cui G, Florholmen J. Polarization of Cytokine Profile From Th1 into Th2 Along Colorectal Adenoma-Carcinoma Sequence: Implications for the Biotherapeutic Target?. Inflamm Allergy Drug Targets 2008, 2:94-97.
39. Beatty G, Paterson Y. IFN-Gamma-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-Gamma. J Immunol 2001, 4:2276-2282.
40. Ikeda H, Old LJ, Schreiber RD. The Roles of IFN Gamma in Protection Against Tumor Development and Cancer Immunoediting. Cytokine Growth Factor Rev 2002, 2:95-109.
41. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. N Engl J Med 2005, 25:2654-2666.
42. Hirata N, Yanagawa Y, Satoh M, Ogura H, Ebihara T, Noguchi M, Matsumoto M, Togashi H, Seya T, Onoe K, Iwabuchi K. Dendritic Cell-Derived TNF-Alpha Is Responsible for Development of IL-10-Producing CD4+ T Cells. Cell Immunol 2010, 1:37-41.
43. Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S. TNF-Alpha-Treated DC Exacerbates Disease in a Murine Tumor Metastasis Model. Cancer Immunol Immunother 2009,
44. Radfar S, Martin H, Tilkin-Mariame AF. [Tumor Escape Mechanism Involving Fas and Fas-L Molecules in Human Colorectal Tumors]. Gastroenterol Clin Biol 2000, 12:1191-1196.
45. Ryan AE, Shanahan F, O'Connell J, Houston AM. Fas Ligand Promotes Tumor Immune Evasion of Colon Cancer in Vivo. Cell Cycle 2006, 3:246-249.
46. Sheehan KM, O'Donovan DG, Fitzmaurice G, O'Grady A, O'Donoghue DP, Sheahan K, Byrne MF, Conroy RM, Kay EW, Murray FE. Prognostic Relevance of Fas (APO-1/CD95) Ligand in Human Colorectal Cancer. Eur J Gastroenterol Hepatol 2003, 4:375-380.